Addictovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.
HP2 Laboratory, Inserm U1300, Grenoble Alpes University, Grenoble, France.
JAMA Netw Open. 2023 Aug 1;6(8):e2331398. doi: 10.1001/jamanetworkopen.2023.31398.
The DRAMES (Décès en Relation avec l'Abus de Médicaments Et de Substances) register is a database of drug-related deaths with the aim of identifying the psychoactive substances associated with and estimating the trends in these deaths. Our novel approach is based on the collection of data on all deaths for which toxicology experts have performed analyses.
To describe drug-related deaths in France and report trends over an 11-year period.
DESIGN, SETTING, AND PARTICIPANTS: This case series used a national register to assess 4460 drug-related deaths that occurred from 2011 to 2021 in France. Data analyses were performed from January 1, 2012, to December 31, 2022.
Demographic characteristics; medical and substance abuse history; forensic autopsy findings; and toxicology reports.
Among the 4460 deceased individuals (mean [SD] age, 37.8 [10.5] years), the mortality rate was highest among men (sex ratio, 4.4:1). Of the deaths involving a single or predominant drug, the legal substitution product, methadone, was the leading cause of death during the entire study period, ahead of heroin-44.7% and 35.9% for methadone vs 15.8% and 21.8% for heroin in 2011 and 2021, respectively. Between 2011 and 2021, most of the drug-related deaths shifted from licit to illicit drugs, and statistically significant variations were found for buprenorphine, cocaine, heroin, methadone, and other licit opioids. Deaths related to polydrug use increased from 23.2% in 2011 to 30.6% in 2021. In this context, opioids remained associated with most deaths, with at least 1 opioid being involved in approximately 9 of 10 cases (85.9%) in 2021. However, the main trend was the dramatic increase in drug combinations with cocaine, from less than one-third of cases in 2011 (30.8%) to more than half in 2021 (57.8%).
This case series assessment of 4460 drug-related deaths found that opioids used alone or in combination were the main contributor to drug-related deaths, despite having a lower prevalence than other drugs. This finding is similar to that of other countries; however, in France licit methadone was the leading cause of opioid-related deaths (ahead of heroin) during the study period. Deaths associated with use of cannabis, new psychoactive substances, and stimulants (including amphetamine-type stimulants and cocaine, especially in combination) have increased and should be closely monitored.
DRAMES(与滥用药物和物质有关的死亡)登记册是一个与药物相关的死亡数据库,旨在确定与这些死亡相关的精神活性物质,并估计这些死亡的趋势。我们的新方法基于对所有进行毒物学分析的死亡案例的数据收集。
描述法国的药物相关死亡情况,并报告 11 年期间的趋势。
设计、地点和参与者:本病例系列使用国家登记册评估了 2011 年至 2021 年期间在法国发生的 4460 例药物相关死亡。数据分析于 2012 年 1 月 1 日至 2022 年 12 月 31 日进行。
人口统计学特征;医疗和药物滥用史;法医尸检结果;以及毒理学报告。
在 4460 名死者中(平均[标准差]年龄,37.8[10.5]岁),男性的死亡率最高(性别比为 4.4:1)。在涉及单一或主要药物的死亡中,合法替代药物美沙酮是整个研究期间的主要死因,2011 年和 2021 年美沙酮分别领先海洛因 44.7%和 35.9%,而海洛因分别领先 15.8%和 21.8%。在 2011 年至 2021 年期间,大多数与药物相关的死亡从合法药物转为非法药物,并且布比卡因、可卡因、海洛因、美沙酮和其他合法阿片类药物的变化具有统计学意义。与多药使用相关的死亡从 2011 年的 23.2%增加到 2021 年的 30.6%。在这种情况下,阿片类药物仍然与大多数死亡有关,大约每 10 例(2021 年为 85.9%)中有 9 例至少涉及 1 种阿片类药物。然而,主要趋势是可卡因与药物的组合急剧增加,从 2011 年不到三分之一的病例(30.8%)增加到 2021 年的一半以上(57.8%)。
本病例系列评估了 4460 例药物相关死亡,发现单独或联合使用的阿片类药物是导致药物相关死亡的主要原因,尽管其流行率低于其他药物。这一发现与其他国家相似;然而,在法国,合法美沙酮是研究期间阿片类药物相关死亡(领先于海洛因)的主要原因。与使用大麻、新型精神活性物质和兴奋剂(包括苯丙胺类兴奋剂和可卡因,尤其是联合使用)相关的死亡有所增加,应密切监测。